Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II clinical trial to evaluate the efficacy of Zoryve (roflumilast) cream 0.05% for treating atopic dermatitis in infants. The INTEGUMENT-INFANT trial represents a significant step toward addressing a prevalent inflammatory skin condition among young children.